MARKET

MDGL

MDGL

Madrigal Pharmac
NASDAQ
208.32
-27.29
-11.58%
After Hours: 207.99 -0.33 -0.16% 16:15 12/08 EST
OPEN
226.00
PREV CLOSE
235.61
HIGH
227.94
LOW
194.88
VOLUME
1.00M
TURNOVER
0
52 WEEK HIGH
322.67
52 WEEK LOW
57.21
MARKET CAP
4.11B
P/E (TTM)
-10.8269
1D
5D
1M
3M
1Y
5Y
Why Comtech Telecommunications Shares Are Trading Lower By Over 16%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Comtech telecommunications corp. Shares fell 16.4% to $10.45 on friday. Comtech telecom reported weak quarterly earnings. Gainers intensity therapeutics, inc. Shares jumped 149.2% after the company presented new data. Mbia shares climbed 63.8% after announcing a special dividend.
Benzinga · 14h ago
These 2 Stocks Could Be About to Soar: Are They Buys?
Madrigal pharmaceuticals and bluebird bio expect to land major approvals in the coming months. Madrigal could be the first to launch an approved therapy for non-alcoholic steatohepatitis. Bluebird has two products on the market for rare blood diseases.
The Motley Fool · 1d ago
89bio: Despite Peer Trial Setback, Potential Remains In NASH
89bio, inc.'s successful end-of-phase 2 meeting with the fda gained alignment for potential accelerated approval of pegozafermin. Akero therapeutics, inc. Failed to achieve the primary endpoint in a nash trial. 89bio has great potential to target the non-alcoholic steatohepatitis market.
Seeking Alpha · 2d ago
Madrigal Pharmac: Statement of changes in beneficial ownership of securities
Press release · 2d ago
Tracking Baker Brothers Portfolio - Q3 2023 Update
Baker brothers' 13f portfolio value increased marginally from $17.28b to $ 17.35b in q3 2023. The largest five stakes in the portfolio are seagen, beigene, incyte, acadia pharma, and biomarin pharma. Stake increases were seen in rhythm pharma, abcellera biologics, and kymera therapeutics.
Seeking Alpha · 4d ago
Weekly Report: what happened at MDGL last week (1127-1201)?
Weekly Report · 4d ago
Madrigal Pharmac: Statement of changes in beneficial ownership of securities
Press release · 12/01 22:26
Worried About a Weight-Loss Stock Bubble? Here Are Some Alternatives.
Eli lilly and novo nordisk are leaders in the market for treating obesity plus diabetes. Obesity is one of the biggest commercial drug opportunities ever, analysts say. Obesity meds could be worth $67 billion in annual sales by 2032, barclays says. Amgen, pfizer and others are also developing obesity drugs.
Barron‘s · 12/01 09:30
More
About MDGL
Madrigal Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH). The Company's product candidate, resmetirom, is a proprietary, liver-directed, selective thyroid hormone receptor-B (THR-B), agonist being developed as a once-daily oral pill for the treatment of NASH. NASH is a more advanced form of non-alcoholic fatty liver disease (NAFLD). NASH is a liver disease that affects people with metabolic diseases, such as obesity and diabetes and non-alcoholic fatty liver disease (NAFLD).

Webull offers Madrigal Pharmaceuticals Inc stock information, including NASDAQ: MDGL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MDGL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MDGL stock methods without spending real money on the virtual paper trading platform.